Montreal, March 9, 2018 – We are proud to announce that EMcision recently completed the CTS acceleration program.  After two years of combined efforts focusing on commercialization of their technology in numerous countries, the company has been acquired by Boston Scientific.  A world leader in medical devices for the last 35 years, Boston Scientific will now enhance their portfolio with the Habib™EndoHPB, designed by EMcision, that is well adapted to improve treatment of diseases such as cholangiocarcinoma and pancreatic cancer.

EMcision now heads down a new path by joining Boston Scientific.  Their global footprint will give the product better visibility, and likely result in a larger number of patients benefiting from this innovation in their fight against these devastating cancers.  It also promises an exciting development for EMcision and its team.

« This new chapter in EMcision’s history will enhance the accessibility of our innovations ,» says Francois Poulin, General Manager of EMcision, « and open up new markets that we could not penetrate on our own .»

For CTS, this success confirms once again the quality of our program and the importance of supporting medical device companies from the onset of their commercialization phase.  In fact, combining financing assistance with mentoring during this critical period allows companies to reach sales levels sufficient to draw the attention of strategic partners or potential investors.  EMcision is the second company from the CTS program to reach this second step.

«We congratulate the great achievements of François Poulin and his team. We are proud of the confidence that EMcision has in the CTS’s unique approach of accelerating medical technology companies by following a personalized coaching program customized to the med tech field,» said Guillaume Hervé, chairman of the board. « The CTS portfolio has several promising companies that can build on the success of EMcision.

CTS would like to highlight the excellent collaboration with EMcision’s team and wishes them the best for the future.

Link to the official Boston Scientific press release:

http://www.nbc12.com/story/37645829/boston-scientific-announces-acquisition-of-emcision-limited

 

ABOUT CTS

CTS is an accelerator for medical device companies.  They offer support to enable faster business development, and increases their chances for industry success.  For more information, visit ctssante.com.

 

CTS

28-300 rue Saint-Sacrement

Montréal (QC) H2Y 1X4

Please communicate with Romain Lortille Bruel for further information : 514 274-1001.

Menu